Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines
Introduction. Risankizumab is a humanized monoclonal antibody of the immunoglobulin G1 (IgG1) type that binds selectively, and with high affinity, to the p19 subunit of interleukin-23 (IL-23), resulting in the inhibition of inflammation and clinical symptoms associated with psoriasis. Its introducti...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/12/11/1883 |
| _version_ | 1797464814004469760 |
|---|---|
| author | Ricardo Ruiz-Villaverde Lourdes Rodriguez-Fernandez-Freire Amalia Pérez-Gil Pilar Font-Ugalde Manuel Galán-Gutiérrez |
| author_facet | Ricardo Ruiz-Villaverde Lourdes Rodriguez-Fernandez-Freire Amalia Pérez-Gil Pilar Font-Ugalde Manuel Galán-Gutiérrez |
| author_sort | Ricardo Ruiz-Villaverde |
| collection | DOAJ |
| description | Introduction. Risankizumab is a humanized monoclonal antibody of the immunoglobulin G1 (IgG1) type that binds selectively, and with high affinity, to the p19 subunit of interleukin-23 (IL-23), resulting in the inhibition of inflammation and clinical symptoms associated with psoriasis. Its introduction has managed to increase the levels of efficacy and safety (improving upon those previously presented by the anti-IL-23 class). Material and methods. Retrospective analysis of a multicenter, observational study of real clinical practice, including patients with moderate-to-severe plaque psoriasis in treatment with risankizumab. This cross-sectional analysis includes information on patients from May 2020 to June 2022. A total of six tertiary hospitals in Andalusia (Spain) participated in this study. Analyses were performed “as observed” using GraphPad Prism version 8.3.0 for Windows. Results. Regarding the percentage of patients who reached PASI 90 or PASI 100 at week 52, 92.5% achieved the therapeutic goal of PASI 90, and 78.5% reached PASI 100. When analyzing the results by absolute PASI, we found that 78.5% (<i>n</i> = 33) obtained PASI 0, 85.7% (<i>n</i> = 36) obtained PASI ≤ 1, and all patients achieved PASI ≤ 3 (disease control). Discussion. Risankizumab has shown promising results in the control of psoriasis in the long-term, with a high percentage of patients (>80%) maintaining PASI 90 and PASI 100 up to 52 weeks of treatment. No abnormal safety findings have been reported, and risankizumab appears to be a solid treatment in the different scenarios analyzed. |
| first_indexed | 2024-03-09T18:12:29Z |
| format | Article |
| id | doaj.art-1a9fd6d5f9224841aa9efe41d2646a74 |
| institution | Directory Open Access Journal |
| issn | 2075-1729 |
| language | English |
| last_indexed | 2024-03-09T18:12:29Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj.art-1a9fd6d5f9224841aa9efe41d2646a742023-11-24T08:57:26ZengMDPI AGLife2075-17292022-11-011211188310.3390/life12111883Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic GuidelinesRicardo Ruiz-Villaverde0Lourdes Rodriguez-Fernandez-Freire1Amalia Pérez-Gil2Pilar Font-Ugalde3Manuel Galán-Gutiérrez4Dermatology Department, Hospital Universitario San Cecilio, 18016 Granada, SpainDermatology Department, Hospital Universitario Virgen del Rocio, 41013 Sevilla, SpainDermatology Department, Hospital Universitario Virgen de Valme, 41014 Sevilla, SpainRheumatology Department, Hospital Universitario Reina Sofía, 14004 Córdoba, SpainDermatology Department, Hospital Universitario Reina Sofía, IMIBIC, 14004 Córdoba, SpainIntroduction. Risankizumab is a humanized monoclonal antibody of the immunoglobulin G1 (IgG1) type that binds selectively, and with high affinity, to the p19 subunit of interleukin-23 (IL-23), resulting in the inhibition of inflammation and clinical symptoms associated with psoriasis. Its introduction has managed to increase the levels of efficacy and safety (improving upon those previously presented by the anti-IL-23 class). Material and methods. Retrospective analysis of a multicenter, observational study of real clinical practice, including patients with moderate-to-severe plaque psoriasis in treatment with risankizumab. This cross-sectional analysis includes information on patients from May 2020 to June 2022. A total of six tertiary hospitals in Andalusia (Spain) participated in this study. Analyses were performed “as observed” using GraphPad Prism version 8.3.0 for Windows. Results. Regarding the percentage of patients who reached PASI 90 or PASI 100 at week 52, 92.5% achieved the therapeutic goal of PASI 90, and 78.5% reached PASI 100. When analyzing the results by absolute PASI, we found that 78.5% (<i>n</i> = 33) obtained PASI 0, 85.7% (<i>n</i> = 36) obtained PASI ≤ 1, and all patients achieved PASI ≤ 3 (disease control). Discussion. Risankizumab has shown promising results in the control of psoriasis in the long-term, with a high percentage of patients (>80%) maintaining PASI 90 and PASI 100 up to 52 weeks of treatment. No abnormal safety findings have been reported, and risankizumab appears to be a solid treatment in the different scenarios analyzed.https://www.mdpi.com/2075-1729/12/11/1883risankizumabpsoriasislong-termreal-world evidence |
| spellingShingle | Ricardo Ruiz-Villaverde Lourdes Rodriguez-Fernandez-Freire Amalia Pérez-Gil Pilar Font-Ugalde Manuel Galán-Gutiérrez Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines Life risankizumab psoriasis long-term real-world evidence |
| title | Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines |
| title_full | Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines |
| title_fullStr | Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines |
| title_full_unstemmed | Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines |
| title_short | Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines |
| title_sort | risankizumab efficacy safety and survival in the mid term 52 weeks in real clinical practice in andalusia spain according to the therapeutic goals of the spanish psoriatic guidelines |
| topic | risankizumab psoriasis long-term real-world evidence |
| url | https://www.mdpi.com/2075-1729/12/11/1883 |
| work_keys_str_mv | AT ricardoruizvillaverde risankizumabefficacysafetyandsurvivalinthemidterm52weeksinrealclinicalpracticeinandalusiaspainaccordingtothetherapeuticgoalsofthespanishpsoriaticguidelines AT lourdesrodriguezfernandezfreire risankizumabefficacysafetyandsurvivalinthemidterm52weeksinrealclinicalpracticeinandalusiaspainaccordingtothetherapeuticgoalsofthespanishpsoriaticguidelines AT amaliaperezgil risankizumabefficacysafetyandsurvivalinthemidterm52weeksinrealclinicalpracticeinandalusiaspainaccordingtothetherapeuticgoalsofthespanishpsoriaticguidelines AT pilarfontugalde risankizumabefficacysafetyandsurvivalinthemidterm52weeksinrealclinicalpracticeinandalusiaspainaccordingtothetherapeuticgoalsofthespanishpsoriaticguidelines AT manuelgalangutierrez risankizumabefficacysafetyandsurvivalinthemidterm52weeksinrealclinicalpracticeinandalusiaspainaccordingtothetherapeuticgoalsofthespanishpsoriaticguidelines |